SCHEMBL7034282

SCHEMBL7034282

O=S(=O)(OC1=CC(CF)(CF)Oc2ccc(C(F)(F)F)cc21)C(F)(F)F

nearest known ligand 0.31

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.31
CHRM1 P11229 1/20 0.31
PTGS1 P23219 1/20 0.30
PTGS2 P35354 1/20 0.30
PPARA Q07869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8137883 0.83 PTGS2 (0.34) PTGDR2PTGS2
SCHEMBL8135352 0.82 PDE4A (0.34) PTGDR2CHRM1PTGS2
SCHEMBL17026934 0.80 PPARA (0.33) PTGDR2PPARA
SCHEMBL6270480 0.75 PTGS1 (0.38) PTGDR2PTGS1PTGS2
SCHEMBL7090383 0.74 OPRD1 (0.32) CHRM1
SCHEMBL17026999 0.73 PPARG (0.36) PTGDR2PPARA
SCHEMBL7093856 0.73 PTGDR2 (0.33) PTGDR2PTGS1PTGS2
SCHEMBL7093857 0.73 CHRM1 (0.33) PTGDR2CHRM1PTGS1PTGS2
SCHEMBL18580411 0.72 PTGDR2 (0.33) PTGDR2PPARA
SCHEMBL6557433 0.72 ALDH1A1 (0.33) PTGDR2PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608217-B2 Process for producing 4-substituted benzopyran derivatives CENTRAL GLASS COMPANY, LIMITED (JP) 2003-08-19 US disclosed
US-20030109574-A1 Process for producing 4-substituted benzopyran derivatives CENTRAL GLASS COMPANY, LIMITED (JP) 2003-06-12 US disclosed
EP-1298129-A2 Process for producing 4-sustituted benzopyran derivatives Central Glass Company, Limited (JP) 2003-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109574-A1 Process for producing 4-substituted benzopyran derivatives ACSL4, HAO2, ACSL6 PTGDR2 1658/4885CHRM1 3098/4885PTGS1 1801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.